Sign in

You're signed outSign in or to get full access.

Eugene Park

Vice President and equity research analyst at Robert W. Baird & Co. Incorporated

Eugene Park is a Vice President and equity research analyst at Robert W. Baird & Co. Incorporated, specializing in financial sector coverage, including regional banks and specialty finance companies. He provides research and recommendations on firms such as U.S. Bancorp, Regions Financial, and Fifth Third Bancorp, achieving a track record that includes a success rate above 60% and notable returns recognized on platforms like TipRanks. Park began his career in financial analysis after earning advanced business credentials and has held positions of increasing responsibility since joining Baird in the early 2010s, following prior analyst experience at a national consulting firm. He holds FINRA Series 7, 63, and 86/87 securities licenses and is recognized for his analytical rigor and sector expertise.

Eugene Park's questions to QUEST DIAGNOSTICS (DGX) leadership

Question · Q4 2025

Eugene Park asked for quantification of the setup costs associated with Fresenius Medical Care and Corewell Health, a breakdown of Project Nova's impact in Q4 2025, and further color on any remaining setup work and potential impacts in Q1 2026.

Answer

CFO Sam Samad explained that Q4 2025 saw a significant impact from the setup and integration expenses for both Fresenius Medical Care and Corewell Health, as these new partnerships involve substantial initial costs. He also confirmed that Project Nova incurred expenses in Q4 2025, consistent with prior statements about costs being pushed out due to a delayed Epic contract signing. For 2026, Mr. Samad quantified Project Nova's impact at approximately $0.25 in incremental expenses, which he expects to be spread fairly evenly across the quarters, possibly with a slight front-loading in the first half.

Ask follow-up questions

Fintool

Fintool can predict QUEST DIAGNOSTICS logo DGX's earnings beat/miss a week before the call

Eugene Park's questions to LABCORP HOLDINGS (LH) leadership

Question · Q3 2025

Eugene Park asked for more color on biopharma laboratory services (BLS) bookings, differentiating between central laboratories and early development, and acknowledging the chunky nature of central lab bookings.

Answer

Chairman and CEO Adam Schechter stated the overall book-to-bill was 0.9 for the quarter, lower than the desired 1.0-1.05, but the trailing 12-month book-to-bill remained strong at 1.09. He expects Q4 book-to-bill to improve sequentially. Central laboratory book-to-bill remains very strong. For early development, book-to-bill is typically lower due to shorter study durations, with delayed study starts being the primary issue, not RFPs or win rates.

Ask follow-up questions

Fintool

Fintool can predict LABCORP HOLDINGS logo LH's earnings beat/miss a week before the call

Question · Q3 2025

Eugene Park of Baird requested more specific color on the Biopharma Laboratory Services (BLS) bookings, differentiating between central laboratories and early development, and commenting on the demand environment for each.

Answer

Chairman and CEO Adam Schechter noted the overall quarterly book-to-bill was 0.9, with a strong trailing 12-month book-to-bill of 1.09. He explained that central laboratory bookings remain very strong, while early development bookings are more challenging to measure due to shorter study durations. For early development, RFP volume and win rates are strong, but delayed study starts are the primary issue.

Ask follow-up questions

Fintool

Fintool can write a report on LABCORP HOLDINGS logo LH's next earnings in your company's style and formatting